Online inquiry

IVTScrip™ pSP6-VEE-mRNA-Anti-IL21, BOS161721 Vector   (CAT#: GTVCR-WQ797MR)

This product GTVCR-WQ797MR is an effective transcription system suitable for a variety of research, including the in vitro translation, self-amplifying mRNA studies and protein expression. The system was driven by the SP6 promoter to efficiently generate mRNA ecoding antibody which targeting IL21. The vector contains the self-replicating Venezuelan equine encephalitis (VEE) virus RNA replicon, which resulting the mRNA expression at a high level.

SPECIFIC INQUIRY

3' poly(A):
Inquiry
Specifications
Product type Vector
Promoter SP6
Resistance Ampicillin
Species Humanized
RefSeq NM_001207006.3
Applications IVT; Self-amplifying mRNA (SAM) research; Gene therapy research
Format Solution
Concentration 1 µg/µl
Quantity 10 µg
Target Gene
Gene ID 59067
UniProt ID Q9HBE4
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ pSP6-VEE-mRNA-Anti-IL21, BOS161721 Vector (GTVCR-WQ797MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTVCR-WQ2222MR IVTScrip™ pSP6-VEE-mRNA-Anti-MSTN, PF-06252616 Vector Vector PF-06252616
GTVCR-WQ1402MR IVTScrip™ pSP6-VEE-mRNA-Anti-MUC1, hPAM4 Vector Vector hPAM4
GTVCR-WQ1070MR IVTScrip™ pSP6-VEE-mRNA-Anti-MSTN, CSL-362-AML Vector Vector CSL-362-AML
GTVCR-WQ2543MR IVTScrip™ pT7-VEE-mRNA-Anti-TNFSF13&TNFSF13B, TACI-Fc Vector Vector TACI-Fc
GTVCR-WQ2247MR IVTScrip™ pT7-VEE-mRNA-Anti-TNFRSF10B, PRO95780 Vector Vector PRO95780
GTVCR-WQ2418MR IVTScrip™ pSP6-VEE-mRNA-Anti-IGF1R, RO4858696-000 Vector Vector RO4858696-000
GTVCR-WQ2643MR IVTScrip™ pT7-VEE-mRNA-Anti-CD3E&IL3RA, XmAb14045 Vector Vector XmAb14045
GTVCR-WQ673MR IVTScrip™ pSP6-VEE-mRNA-Anti-LTB&TNFSF14, BG9924 Vector Vector BG9924
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW